BeiGene's Stock Surges 72.23% in Trading Volume Ranking 446th Amidst Biotech Boom

On July 17, 2025, BeiGene's trading volume reached HK$234 million, marking a 72.23% increase from the previous day. The company's stock ranked 446th in terms of trading volume for the day. BeiGene's shares have been on a steady rise, increasing by 4.01% and marking the fourth consecutive day of gains, with a total increase of 16.00% over the past four days.

BeiGene's Hong Kong-listed shares experienced a significant surge following the acceptance of its DLL3/CD3 bispecific antibody, tarlatamab, for review. This development has sparked investor interest and contributed to the company's recent stock performance.

Biotechnology stocks, including BeiGene, showed strong performance. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. rose by 23.90%, KEYMED BIO-B increased by 12.40%, and AKESO gained 10.16%. Innovative drug concept stocks also performed well, with Lepu Biopharma leading the way with a rise of over 13%. KEYMED BIO-B increased by over 12%, AKESO rose by more than 10%, and INNOVENT BIO, WUXI BIO, and Hengrui Pharmaceuticals all saw gains.